Matinas BioPharma
MTNB
67 hedge funds and large institutions have $29.2M invested in Matinas BioPharma in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 22 closing their positions.
0.03% less ownership
Funds ownership: 0.4% → 0.37% (-0.03%)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
16% less funds holding
Funds holding: 80 → 67 (-13)
30% less capital invested
Capital invested by funds: $41.7M → $29.2M (-$12.5M)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.45M |
| 2 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
+$1.29M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$516K |
| 4 |
State Street
Boston,
Massachusetts
|
+$451K |
| 5 |
Renaissance Technologies
New York
|
+$403K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$3.76M |
| 2 |
HF
HRT Financial
New York
|
-$780K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$666K |
| 4 |
BlackRock
New York
|
-$408K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$400K |
MTNB Hedge Fund Activity: Q2 2021 in Review
67 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2021, worth a combined $29.2M — down 30% from $41.7M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of MTNB and 9 opened new positions — a net loss of 13 holders — while 14 trimmed existing stakes and 13 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $1.45M. The largest seller was Anson Funds Management, exiting entirely with an estimated $3.76M sold.
- 67 institutional investors held Matinas BioPharma (MTNB) as of Q2 2021, down from 80 in Q1 2021.
- Funds reported $29.2M of Matinas BioPharma stock for Q2 2021, down 30% quarter-over-quarter.
- 9 funds opened new Matinas BioPharma positions in Q2 2021 and 22 closed out, a net change of -13 holders.
- The largest Matinas BioPharma buyer in Q2 2021 was GSA Capital Partners, an estimated $1.45M added.
- The largest Matinas BioPharma seller in Q2 2021 was Anson Funds Management, an estimated $3.76M sold.
Based on aggregated 13F filings for Q2 2021.